DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/l4hbfj/critical_limb) has announced the addition of the "Critical Limb Ischemia - Pipeline Review, H1 2015" report to their offering.
This report provides comprehensive information on the therapeutic development for Critical Limb Ischemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Critical Limb Ischemia and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Companies Involved in Therapeutics Development
- AnGes MG, Inc.
- Apceth GmbH & Co. KG
- Athersys, Inc.
- Bioheart, Inc.
- DNAVEC Corporation
- Hemostemix Ltd
- IntelliCell BioSciences Inc.
- Juventas Therapeutics, Inc.
- Kasiak Research Pvt. Ltd.
- Multi Gene Vascular Systems Ltd
- NeoStem, Inc.
- Pharmicell Co., Ltd.
- Pluristem Therapeutics Inc.
- ReNeuron Group plc
- Stempeutics Research Private Limited
- TikoMed AB
- Vericel Corporation
- ViroMed Co., Ltd.
Drug Profiles
- ACP-01
- AdipoCell
- Alecmestencel-T
- AMR-001
- ASCT-01
- Autologous Vascular Cells Therapy
- beperminogene perplasmid
- Cell Therapy for Critical Limb Ischemia
- Cellgram for Severe Lower Limb Ischemia
- DVC1-0101
- Gene Therapy for Critical Limb Ischemia and Peripheral Arterial Disease
- Gene Therapy to Activate Vascular Endothelial Growth Factor for Cardiovascular Disease and Central Nervous System Disorders
- ixmyelocel-T
- JVS-100
- MultiGeneAngio
- MultiStem
- PLX-PAD
- Protein for Myocardial Infarction and Critical Limb Ischemia
- Recombinant Protein for Critical Limb Ischemia
- Refacell-CLI
- ReN-009
- Stem Cell Therapy for Critical Limb Ischemia
- Stem Cell Therapy for Critical Limb Ischemia
- Stem Cell Therapy to Activate VEGF for Critical Limb Ischemia
- Stempeucel
- Stromal Cell Therapy for Critical Limb Ischemia
- TM-700
- VM-202
For more information visit http://www.researchandmarkets.com/research/l4hbfj/critical_limb
